Kornimate/medical-research-clean huggingface dataset:
boosting the intervention effect of negative memory through tacs stimulation

Conditions: Seizures

Summary: the objectives of this study include: 1) investigating the impact of negative memory substitution on an individual's other intellectual memories (i.e., neutral memories) and the underlying neurocognitive mechanisms; 2) investigating the memory enhancement effect resulting from retrieval practice associated with memory substitution intervention along with an examination of the neurocognitive mechanisms responsible for this enhancement.

this study will adopt two memory updating strategies: retrieval practice and reactivation. a 5-day memory updating experimental paradigm is used. 1. on the first day, the old memory a-b linkage is learned, where a represents a neutral word and b is either neutral or negative pictures (half of each, randomly scrambled). 2. on the second day, the old memory a-b association is consolidated again, and after a 15-minute break, the new memory a-c association is learned, where a is still the word a used in the old memory a-b association on the first day, and c is the new neutral and negative pictures (half of each, randomly scrambled, and with inconsistent categories of c and b in each pair of ac and ab). immediately following this, the new memories of the a-c conjunctions are updated using both retrieval practice and restudy (control condition) memory strategies. 3. a-c is extracted/learned using both retrieval practice and restudy memory strategies on both day 3 and day 4. 4. on the fifth day, memory tests for associative memory strength, gist and detail memory, as well as emotional valence and strength are performed.

Eligibility criteria:
eligibility inclusion criteria: 1. 14-60 years old, male or female, han chinese; 2. drug-resistant epilepsy; 3. required surgical implantation of seeg electrodes. exclusion criteria: 1. progressive encephalopathy or progressive structural damage in the central nervous system; 2. significant heart, liver, renal insufficiency, and other medical diseases; 3. severe side effects from taking antiepileptic drugs at the time of enrollment and not inappropriate for seeg; 4. significant intellectual disability; 5. a history of alcohol and drug abuse; 6. any contraindication to mri.

Keywords: seizure transcranial alternating current stimulation neuromodulation negative memory neural mechanisms retrieval practice working memory
safety and feasibility of using epicall for monitoring pre-seizure biomarkers

Conditions: Seizure

Summary: epilepsy is a syndrome of episodic brain dysfunction characterized by recurrent seemingly unpredictable spontaneous seizures. the occurrence of the seizure in patients without any forewarning is the most debilitating aspect of the disease. the epicall system is intended for early detection of seizure related life threatening events by monitoring per-seizures biomarkers. the system is based on a sticker placed on the side of the face. the external sticker incorporates eog (electrooculograph electrode) and ppg (photoplethysmograph electrode) sensors for continuous monitoring of: 1. heart rate (base line, increase, decrease, asystole). 2. extra ocular eye movement (blinking, eye deviation, roving eye movements).


Eligibility criteria:
inclusion criteria: * children age 1 year -18 years old. * hospitalized patient who is diagnosed with epilepsy. * patient's parents/care giver able to comprehend and give informed consent for participation in this study. * patient's parents/care giver must commit to both screening and monitoring visits. * patient's parents/care giver must sign the informed consent form. exclusion criteria: * patient with any infection / abscess / bleeding / blister / crack / edema / fissure / ulcer / pain in monitoring electrode area * general weakness. * patient's parents/care giver objects to the study protocol. * concurrent participation in any other clinical study. * physician objection.

Keywords: seizure early detection
surveillance of regional nodal basins in patients with primary high risk cutaneous squamous cell carcinoma of the head and neck

Conditions: Cutaneous Squamous Cell Carcinoma of the Head and Neck

Summary: in this prospective cohort study, investigators will conduct ultrasound surveillance of the nodal basins of patients with head and neck cutaneous squamous cell carcinoma (cscc) whose tumors are considered high risk and staged by the brigham and women's hospital (bwh) tumor staging system. the study will enroll patients with tumors staged t2a and who are also immunosuppressed (from solid organ transplant, hematologic malignancy or autoimmune disease), t2b (sentinel lymph node negative), and t3 (sentinel lymph node negative). after two years of surveillance, outcomes regarding local recurrence, nodal metastasis, disease specific death, and overall survival will be compared with historical controls with the overall hypothesis that ultrasound surveillance will detect subclinical disease earlier and help improve outcomes.


Eligibility criteria:
inclusion criteria: * all cscc must be on the head or neck * all cscc must be primary tumors. * bwh stage t2a tumors in patients who are on chronic immunosuppression (organ transplant, hematologic malignancy, autoimmune disease) * all bwh t2b or t3 tumors with a negative ct of the nodal basin and a negative slnb exclusion criteria: * recurrent tumors * patients who are bwh t2b/t3 who have a positive ct of the nodal basin or positive lymph node biopsy

Keywords: ultrasound brigham and women's hospital staging high risk cutaneous squamous cell carcinoma head and neck lymph node basins immunosuppressed bwh
improving bowel preparation for the colon capsule

Conditions: Quality of Bowel Preparation for the Colon Capsule; Colon Capsule Completion Rates; Colon Capsule Polyp Detection

Summary: colon capsule endoscopy is a technology that has been developed as a noninvasive method of examining the large bowel. the biggest limitation to its use has been finding a bowel preparation that will both clean the colon adequately for good visualization of the mucosa and also help propel the capsule through the colon. most studies have been conducted in europe using bowel preparation medications that are not approved for use in north america. the purpose of this study is to compare a combination of polyethylene glycol (peg) and prucalopride to picosalax and prucalopride to determine which regime will give a better colon cleanse for the colon capsule. both peg and picosalax are bowel preparations that are used routinely for colonoscopy in canada. prucalopride is a new medication recently approved for use in canada which improves intestinal motility and should help with colon capsule transit. patients who are being referred for colonoscopy will be enrolled in the study and randomized to one of the bowel preparation regimes. they will undergo a split-dose bowel preparation with either peg or picosalax, which is routine for colonoscopy. as part of the standard bowel preparation, patients randomized to the picosalax group will take dulcolax three nights before the test and then again two nights before the test. the evening before the test patients will take either peg 2l or one sachet of picosalax. the following morning they will take another dose of either peg (2 liter container) or one sachet of picosalax. they will then ingest the colon capsule and a dose of prucalopride that morning. after 7 hours they will return to the endoscopy unit where they will undergo a colonoscopy, which is the standard of care for examination of the colon. the images from the colon capsule will be reviewed and the quality of bowel preparation will be graded using a previously validated scale. it is hypothesized that the picosalax and prucalopride regime will give a better cleanse for the colon than peg and prucalopride as there will be less turbid fluid in the colon and allow for a better view of the mucosa. polyp detection and abnormalities of the mucosa detected with the colon capsule will also be compared to polyps and abnormalities detected at the time of colonoscopy.


Eligibility criteria:
inclusion criteria: * male and female patients between the ages of 18 and 75 * patients being referred for colonoscopy exclusion criteria: * symptoms of dysphagia * bowel obstruction or ileus * known stricture or fistula * inflammatory bowel disease * previous small or large bowel surgery * severe gastroparesis or motility disorder * renal impairment (gfr\<55 within 3 months of study) * congestive heart failure (nyha iii or iv) * ischemic heart disease * cirrhosis or severe hepatic dysfunction (ascites or lab result inr\>2) * history of serious arrhythmia * pregnancy

Keywords: colon capsule picosalax peg prucalopride
a study of guselkumab in participants with fistulizing, perianal crohn's disease

Conditions: Fistulizing Crohns Disease; Perianal Crohns Disease

Summary: the purpose of this study to evaluate the clinical efficacy of guselkumab in fistulizing, perianal crohn's disease and to assess the overall safety of guselkumab.


Eligibility criteria:
inclusion criteria: * must have a diagnosis of crohn's disease with a minimum duration of at least 3 months * has at least one active draining perianal fistula as a complication of crohn's disease, confirmed by screening magnetic resonance imaging (mri) results * has previously demonstrated lack of initial response (that is primary non-responders), responded initially but then lost response with continued therapy (that is secondary non-responders), or were intolerant to a maximum of 2 classes of advanced drug therapies at a dose approved for the treatment of crohn's disease (that is infliximab, adalimumab, certolizumab pegol, vedolizumab, or approved biosimilars for these agents) or jak inhibitors licensed for crohn's disease treatment (that is, upadacitinib) exclusion criteria: * has a very severe luminal disease activity * history of concurrent rectovaginal fistulas (other types of concurrent fistula should be confirmed with the sponsor), rectal and/or anal stenosis, stoma or functioning ostomy (include all current stoma types abscess or collections which are not properly drained) colonic mucosal dysplasia or pre-cancerous lesions that have not been removed, demyelinating disease, or systemic lupus erythematosus * has complications of cd, such as symptomatic strictures or stenoses, short gut syndrome, or any other manifestation that might be anticipated to require surgery or preclude fistula evaluation * any medical contraindications preventing study participation * has a history of ongoing, chronic or recurrent enteral or systemic infectious disease
study of ave1642 anti-igf1r monoclonal antibody in patients with advanced multiple myeloma

Conditions: Multiple Myeloma

Summary: primary objectives: study part 1: determine the selected dose of ave1642 administered every 3 weeks based on pharmacokinetic (pk) (clearance of ave1642), pharmacodynamic (pd) (insulin-like growth factor 1 \[igf-1\] serum level) parameters, and eventual dose limiting toxicities (dlts) in patients with recurrent, refractory multiple myeloma (mm). study part 2: assess the safety of the combination of the selected dose of ave1642 with the recommended dose of velcade®. secondary objectives : study part 1: * to assess the safety profile: type, incidence and intensity of drug related adverse events (aes) * to assess the biological activity of ave1642 (saturation of the receptors and down-regulation) on malignant plasma cells and on peripheral blood mononuclear cells (pbmc) and granulocytes * to assess the biological activity of ave1642 on the signalization pathway of the igf-1 system (phosphorylated akt \[pakt\], phosphorylated erk \[perk\]) on malignant plasma cells when technically possible * to define pk profile of ave1642, and its pd effects on serum igf 1, gf 2 and igfbp-3 * to assess clinical efficacy (complete response \[cr\], partial response \[pr\], minimal response \[mr\] and stabilization) based on the european group for blood and marrow transplantation (ebmt) criteria, when possible * to assess potential immunogenicity by detection of human antihumanized antibodies (haha) anti-ave1642 study part 2: * to detect any pk or pd interaction between ave1642 and velcade® * to assess clinical efficacy (cr, pr, mr, no change \[nc\]) according to ebmt criteria when appropriate * to assess biological activity of ave1642 in combination with velcade® on malignant plasma cells collected from bone marrow aspirates: saturation and down-regulation of the insulin-like growth factor 1 receptor (igf-1r) and activity on the signalization pathway of the igf-1 system (pakt, perk) when feasible * to detect immunogenicity reaction (haha) * to characterize pk and pd profile of a low dose (0.5 mg/kg) of ave1642 expected to be non biologically active


Eligibility criteria:
inclusion criteria: * multiple myeloma confirmed by bone marrow aspirate or biopsy * patient had to have relapsed and/or refractory multiple myeloma after at least 1 standard therapy, and have demonstrated disease progression * previous exposure to velcade was allowed, provided no dlts of grade 3 or above had been observed during previous treatment (for part 2 of the study only) exclusion criteria: * prior therapy with any igf-1 system targeting compound * history of allogenic stem cell transplantation in case of concomitant immunosuppressive therapy within 6 months before study entry. patients having undergone autologous stem cell transplantation(s) may have been included in the study * history of organ transplant and any patient receiving long term systemic immunosuppressive therapy the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
psychosocial factors affecting glycemic control in children and adolescents with type 1 diabetes mellitus

Conditions: Diabetes Mellitus, Type 1

Summary: the aim of the study is to research psychosocial and socioeconomic factors among families that might affect glycemic control in children and adolescent with type 1 diabetes mellitus. these factors might be: living conditions, structure of the family, socioeconomic status, divorces and parent's own glycemic control status (if parent's type 1 diabetes mellitus is present in the family).

this study is going to clarify if there are some socioeconomical or psychosocial factors that might influence child's type 1 diabetes mellitus glycemic control. study population consists of 300-350 diabetic children aged 1-16 years who have diabetic controls at tampere university hospital and their families. required information is going to be collected with 2 questionnaires, wich families are kindly asked to fill in.

Eligibility criteria:
inclusion criteria: type 1 diabetic children aged 1-16 years and their parents. patient's and parents' willingness to participate exclusion criteria: type 1 diabetes duration under 1 year. difficulties to understand written finnish. -

Keywords: glycemic control children psychosocial and socioeconomic factors
hiv and fat accumulation

Conditions: HIV Infection

Summary: this is a research study to see whether fat accumulation either under the skin or in the body's organs, for example, the liver, improves in men and women who take a drug called telmisartan. the investigators will be looking at how the amount of fat in the body changes when hiv-positive persons on effective anti-hiv therapy take telmisartan. the investigators will be using a ct scan to make this comparison. telmisartan is not an hiv medication. it is a medication used to treat blood pressure, but has been shown to decrease fat in the organs in people both with and without high blood pressure. the study involves 8 visits over a period of about 24 weeks.


Eligibility criteria:
inclusion criteria: * hiv positive men and women 18 years and older * hiv-1 infection as documented by elisa and confirmed by western blot or plasma hiv-1 rna \>2000 on two occasions * documented central fat accumulation * hiv rna documented to be less than 50 copies/ml at screening and undetectable by assay of choice for at least 12 weeks prior to entry * current antiretroviral therapy with a suppressive, highly active antiretroviral regimen. * systolic bp \>115mmhg. * ability and willingness to provide informed consent exclusion criteria: * pregnancy (current or within the last 6 months) or nursing * uncontrolled hypertension * prohibited concomitant medications * subjects with untreated hyperlipidemia must be willing to abstain from initiating therapy for the 24 week duration fo the study. * subjects undergoing treatment for diabetes with oral hypoglycemic agents must be willing to remain on their current dose of insulin sensitizing agents for the duration of the study. * known, untreated renal artery stenosis * unstable coronary artery disease/angina or decompensated congestive heart failure. * any history of intolerance to any member of the angiotensin receptor blocker class of agents. * need for ongoing potassium supplementation. * screening laboratory values as follows anc (absolute neutrophil count) \ 3 x uln (upper limit of normal)

Keywords: metabolic hiv fat accumulation aids metabolic abnormalities in hiv infection hiv infections
effect of preforpro® on urinary and vaginal health

Conditions: Bacterial Vaginosis; Bacterial Infections; Bacterial Vaginosis &#X7C; Vaginal &#X7C; Microbiology; Vaginal Infection

Summary: this study will investigate the effects of preforpro® (prebiotic and bacteriophages (lh01-myoviridae, ll5-siphoviridae, t4d-myoviridae, and ll12-myoviridae, greater \> 6.7 x 107 pfu/gram) on bacterial vaginosis.

this is a double-blinded, placebo controlled study. each study participant will be in the study for 90 days. during the first 28 days the participants will not take study product, and will collect samples for the study in order to act as their own controls. on day 29, participants will be randomized to intervention with either preforpro® or placebo, which they will take once daily for the remaining 62 days. there will be a total of 5 study visits during which samples will be collected, a quality of life questionnaire will be completed at baseline and end of study visit. samples for the study are: vaginal swab, faecal sample, urine sample.

Eligibility criteria:
inclusion criteria: * female * 18-45 years old premenopausal (period within 6 months) * nugent score of 4-6 (intermediate) or 7-10 (bv) * have an ability to collect a clean urine sample * prescription and over the counter medication unchanged for \> 30 days prior to the study. -participants who are taking medications as needed (prn) may be included if they began prn usage \>30 days prior to baseline * sexually active status of the participants can be either active or inactive * participants must agree to use a medically approved method of birth control (e.g. hormonal contraceptives, intrauterine devices, vasectomy/tubal ligation, barrier methods and double-barrier method) and must have negative pregnancy test results at screening and baseline exclusion criteria: * faecal incontinence * history of urinary fistula, bladder or kidney stones, interstitial cystitis, or cystoscopic abnormalities that could be malignant * neurogenic bladder * a history of currently undergoing immunosuppressive drug therapy, chemotherapy, or radiation therapy * antibiotic and/or anti-fungal medication used within the last four weeks * oral probiotic supplement use within 2 weeks prior the study excluding yogurt * drug abuse * uncontrolled psychological disorders
clinical assessment of the total vaginal mesh technique for treatment of genital prolapse

Conditions: Vaginal Prolapse

Summary: pelvic floor prolapse is a general term used to describe various clinical conditions that are associated with pelvic floor (muscles that support the vagina) relaxation in female patients.pelvic floor prolapse is thought to result from a stretching, weakening or tearing of the soft tissue structures that support the pelvic organs. these tissues become compromised because of a weakened or damaged.the purpose of the study will be to demonstrate the usability of polypropylene mesh for prolapse repair, using the tvm technique.


Eligibility criteria:
inclusion criteria: * female candidate for surgical pelvic floor repair (at least ics stage ii symptomatic prolapse). * patient who is at leat 21 years of age. * patient whose family is complete. * patient may not have uncontrolled diabetes. exclusion criteria: * patients may not have coagulation disorders.
music and colposcopy in women with cervical dysplasia.

Conditions: Uterine Cervical Dysplasia

Summary: to assess the effect of music during colposcopy on women´s anxiety.


Eligibility criteria:
inclusion criteria: * women referred for colposcopy due to cervical abnormalities * we included women if they attended colposcopy for the first time exclusion criteria: * pregnant women * presence of a language barrier * known anxiety disorder or depression * history of conization or other treatments on the cervix uteri * known oncological disorder * auditory defect * cardiovascular disease * inadequate colposcopy

Keywords: cervical dysplasia colposcopy anxiety music mozart randomized controlled trial
safety and efficacy of adipose derived regenerative cells (adrcs) delivered via the intracoronary route in the treatment of patients with st-elevation acute myocardial infarction (ami)

Conditions: Acute Myocardial Infarction

Summary: double blind, prospective, randomized, placebo-controlled safety and efficacy trial of adrcs delivered via the intracoronary route in the treatment of patients with st-elevation acute myocardial infarction (stemi).

this is a prospective, randomized, two arm, placebo-controlled, double blind, study that will enroll approximately 216 patients at no more than thirty-five (35) international clinical sites. additional blinding measures will be taken in the assessment of study outcomes. the dose of the test material (adrcs)is described in the protocol. the study will include two arms.

Eligibility criteria:
key inclusion criteria: * st-segment elevation myocardial infarction (stemi) criteria: * ischemic symptoms and * ecg: * development of pathologic q waves on the ecg; or * ecg changes indicative of severe ischemia (st segment elevation and/or depression); or * new left bundle branch block; and * creatine phosphokinase isoenzyme (mb form) \> 100 iu/l, or troponin \>5x the upper limit of normal between admission and randomization * successful revascularization of the culprit lesion in a major epicardial vessel key exclusion criteria: * more than 24 hours between pci and start of liposuction * prior myocardial infarction, cardiomyopathy, or a history of congestive heart failure * pacemaker, icd, or any other contra-indication for mri * patients with increased bleeding risk * cardiogenic shock present post-index pci

Keywords: heart attack regenerative cells stem cells
blood loss evaluation using a novel device

Conditions: Blood Loss, Surgical; Transfusion; Patient Blood Management

Summary: the study´s aim is to evaluate the clinical applicability of the feature extraction technology (fet) during a simulated blood loss scenario.

in an operating theatre blood loss will be simulated in different scenarios. expired whole blood donations (provided by the german red cross, institute of transfusions medicine, goethe university frankfurt) will be used. blood will be diluted by full electrolyte solutions . sponges and canisters will be prepared with a predetermined amount of blood. study participants will estimate total blood loss on sponges and canisters. study members not knowing the correct amount of prepared blood will measure the blood loss in sponges and canisters by feature extraction technology (fet) and by gravimetric method before and after estimation of the participants.

Eligibility criteria:
inclusion criteria: * health care professionals exclusion criteria: * none